WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma Clinical Trial

Official title:

A Phase 1 (First-In-Human [FIH]), Multi-Site, Dose Escalation and Expansion Study of WTX-330 in Adult Patients With Advanced or Metastatic Solid Tumors or Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05678998
• Other study ID #: WTX-330x2101
• Status: Recruiting
• Phase: Phase 1
• Start date: December 6, 2022
• Est. completion date: December 2024

Study information

• Verified date: March 2024
• Source: Werewolf Therapeutics, Inc.
• Contact: Study Director
• Phone: 617-952-0555
• Email: clinicaltrials[@]werewolftx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.

Description:

This is a first-in-human, Phase 1, open-label, multicenter study to evaluate the safety, tolerability and preliminary efficacy of WTX-330, a conditionally-activated IL-12 prodrug, when administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma. Dose escalation will be conducted in patients with advanced and/or metastatic solid tumors who are refractory to all standard of care therapies. Dose expansion will be conducted in two arms: Arm A will enroll patients with indications for which a checkpoint inhibitor (CPI) is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1 treatment regimen, and Arm B will enroll patients with tumor types for which CPI therapy is not indicated/approved.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years.

2. Dose Escalation: A diagnosis of a relapsed/refractory advanced or metastatic solid tumor for which the patient has progressed on or is intolerant of standard therapy, or for whom no standard therapy with proven benefit exists.

3. Dose Expansion: A diagnosis of a relapsed/refractory advanced or metastatic malignancy for which the patient has progressed on or is intolerant of standard therapy, or for whom no standard therapy with proven benefit exists. For Arm A, patients must have a tumor type for which a CPI is indicated/approved and demonstrate primary or secondary resistance to a standard of care anti-PD(L)1-based treatment regimen. For Arm B, patients must have a solid tumor type for which a CPI is not indicated/approved or non-Hodgkin lymphoma.

4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

5. At least one measurable lesion per RECIST 1.1 or an evaluable lesion per Lugano classification (for lymphoma).

6. Agrees to undergo a pre-treatment and on-treatment biopsy of a primary or metastatic solid tumor or lymphoma lesion.

7. HIV-infected patients must be on antiretroviral therapy and have well-controlled disease.

8. Adequate organ and bone marrow function.

9. Willingness of men and women of reproductive potential to use highly effective birth control for the duration of treatment and for 4 months following the last dose of study drug.

10. Additional criteria may apply.

Exclusion Criteria:

1. A history of another active malignancy (i.e., a second cancer) within the previous 2 years, except for localized cancers that are not related to the current cancer being treated, are considered cured, and, in the opinion of the Investigator, present a low risk of recurrence. These exceptions include but are not limited to basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.

2. Received prior treatment with IL-12, including by intratumoral injection.

3. Patients with primary CNS malignancies.

4. Presence of CNS metastases that are symptomatic and/or require local CNS directed therapy (such as XRT or surgery) or increasing doses of corticosteroids within 2 weeks prior to the first dose of study drug. Patients with treated brain metastases should be neurologically stable and receiving = 10 mg per day of prednisone or equivalent prior to study entry.

5. Significant cardiovascular disease.

6. Significant electrocardiogram (ECG) abnormalities

7. Active autoimmune disease requiring systemic treatment in the past 2 years.

8. Diagnosis of immunodeficiency, on immunosuppressive therapy, or receiving chronic systemic or enteric steroid therapy (dose > 10 mg/day of prednisone or equivalent).

9. Prior receipt of an allogeneic stem cell transplant or allogeneic CAR-T cell therapy.

10. Major surgery (excluding placement of vascular access) within 2 weeks prior to the first dose of study drug.

11. Investigational agent or anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, anticancer Chinese medicine, or anticancer herbal remedy) within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug.

12. Radiotherapy within 2 weeks of the start of study treatment. A 1-week washout is permitted for palliative radiation (= 2 weeks of radiotherapy) to non-CNS disease.

13. Any unresolved toxicities from prior therapy greater than NCI-CTCAE version 5.0 Grade 1 at the time of starting study drug with the exception of alopecia and Grade 2 platinum therapy-related neuropathy.

14. Use of sensitive substrates of major CYP450 isozymes.

15. Any illness, medical condition, organ system dysfunction, or social situation (including mental illness or substance abuse), that may interfere with a patient's ability to sign the ICF, adversely affect the patient's ability to cooperate and participate in the study, or compromise interpretation of study results.

16. Received a live vaccine within 30 days of the first dose of study drug.

17. Active, uncontrolled systemic bacterial, viral, or fungal infection.

18. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.

19. Active infection with hepatitis B as determined by hepatitis B surface antigen and hepatitis B core antibody, or hepatitis B virus deoxyribonucleic acid (DNA) by quantitative polymerase chain reaction (qPCR) testing.

20. Active infection with hepatitis C as determined by hepatitis C virus (HCV) antibody or HCV RNA by qPCR testing.

21. Pregnant or lactating.

22. History of hypersensitivity to any of the study drug components.

23. Additional criteria may apply

Related Conditions & MeSH terms

• Advanced or Metastatic Solid Tumors
• Lymphoma
• Lymphoma, Non-Hodgkin
• Non-Hodgkin Lymphoma

Intervention

Drug:
• WTX-330
Investigation Product

Locations

Country	Name	City	State
United States	Emory Winship Cancer Institute of Emory University	Atlanta	Georgia
United States	Mass General Hospital	Boston	Massachusetts
United States	Facility Name: Roswell Park Comprehensive Cancer Care	Buffalo	New York
United States	Northwestern University	Chicago	Illinois
United States	Indiana University	Indianapolis	Indiana
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	Providence Cancer Institute Franz Clinic	Portland	Oregon
United States	NEXT Oncology	San Antonio	Texas
United States	HonorHealth	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Werewolf Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Dose Limiting Toxicities (DLTs)		4 weeks
Primary	Incidence of treatment emergent adverse events		24 months
Primary	Incidence of changes in clinical laboratory abnormalities		24 months
Primary	Investigator-assessed objective response rate (ORR) by RECIST 1.1 and immune ORR by iRECIST (for solid tumors) or response by Lugano criteria (for lymphomas)		24 months
Secondary	Plasma concentrations of WTX-330 and free IL-12		24 months
Secondary	Changes in circulating immune cell populations		24 months
Secondary	Changes in soluble cytokines including IL-2, IL-4, IL-6, IL-10, IFN-? and IP-10		24 months
Secondary	Changes in tumor immune cell profile by immunohistochemistry (IHC)		24 months
Secondary	Investigator-assessed ORR by RECIST 1.1 and immune ORR by iRECIST (for solid tumors) or response by Lugano criteria (for lymphomas) in patients who have progressed on CPIs or who have tumor indications for which CPIs are not approved		24 months
Secondary	Antidrug antibody (ADA) occurrence		24 months
Secondary	Duration of response		24 months
Secondary	Progression free survival		24 months
Secondary	Overall survival		36 months
Secondary	Identification of potential biomarkers of target engagement and immune pathway activation in tumor biopsies		24 months